CL2010001359A1 - Combinacion farmaceutica que comprende metotrexato y un inhibidor de dihidroorato dehidrogenasa (dhodh) derivado de acido bifenil nicotinico o una sal farmaceuticamente aceptable o n-oxido de los mismos. - Google Patents

Combinacion farmaceutica que comprende metotrexato y un inhibidor de dihidroorato dehidrogenasa (dhodh) derivado de acido bifenil nicotinico o una sal farmaceuticamente aceptable o n-oxido de los mismos.

Info

Publication number
CL2010001359A1
CL2010001359A1 CL2010001359A CL2010001359A CL2010001359A1 CL 2010001359 A1 CL2010001359 A1 CL 2010001359A1 CL 2010001359 A CL2010001359 A CL 2010001359A CL 2010001359 A CL2010001359 A CL 2010001359A CL 2010001359 A1 CL2010001359 A1 CL 2010001359A1
Authority
CL
Chile
Prior art keywords
nicotinic acid
dhodh
methotrexate
biphenyl
pharmaceutical combination
Prior art date
Application number
CL2010001359A
Other languages
English (en)
Inventor
Marina Nuria Godessart
Lalanza Maria Pilar Pizcueta
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001359(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of CL2010001359A1 publication Critical patent/CL2010001359A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Combinación farmacéutica que comprende a) metrotexato y b) un inhibidor de DHODH no hepatotóxico, derivados de ácido nicotínico; un kit; un envase; y su uso para artritis reumatoide o psoriatica, espondilitis anquilosante, esclerosis múltiple, entre otras.
CL2010001359A 2008-06-20 2010-12-06 Combinacion farmaceutica que comprende metotrexato y un inhibidor de dihidroorato dehidrogenasa (dhodh) derivado de acido bifenil nicotinico o una sal farmaceuticamente aceptable o n-oxido de los mismos. CL2010001359A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08382022A EP2135610A1 (en) 2008-06-20 2008-06-20 Combination comprising DHODH inhibitors and methotrexate

Publications (1)

Publication Number Publication Date
CL2010001359A1 true CL2010001359A1 (es) 2011-04-08

Family

ID=39930498

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001359A CL2010001359A1 (es) 2008-06-20 2010-12-06 Combinacion farmaceutica que comprende metotrexato y un inhibidor de dihidroorato dehidrogenasa (dhodh) derivado de acido bifenil nicotinico o una sal farmaceuticamente aceptable o n-oxido de los mismos.

Country Status (35)

Country Link
US (1) US8865728B2 (es)
EP (2) EP2135610A1 (es)
JP (1) JP5507551B2 (es)
KR (1) KR101675601B1 (es)
CN (1) CN102065866B (es)
AR (1) AR072174A1 (es)
AU (1) AU2009259625B2 (es)
BR (1) BRPI0909995A2 (es)
CA (1) CA2728976C (es)
CL (1) CL2010001359A1 (es)
CO (1) CO6321267A2 (es)
CY (1) CY1119643T1 (es)
DK (1) DK2296663T3 (es)
EA (1) EA020193B1 (es)
ES (1) ES2641168T3 (es)
HR (1) HRP20171667T1 (es)
HU (1) HUE036639T2 (es)
IL (1) IL209267A (es)
LT (1) LT2296663T (es)
ME (1) ME02903B (es)
MX (1) MX2010013409A (es)
MY (1) MY155249A (es)
NO (1) NO2296663T3 (es)
NZ (1) NZ589089A (es)
PE (1) PE20110149A1 (es)
PL (1) PL2296663T3 (es)
PT (1) PT2296663T (es)
RS (1) RS56584B1 (es)
SG (2) SG10201609515RA (es)
SI (1) SI2296663T1 (es)
TW (1) TWI440462B (es)
UA (1) UA114388C2 (es)
UY (1) UY31897A1 (es)
WO (1) WO2009153043A1 (es)
ZA (1) ZA201008041B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) * 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EA201100605A1 (ru) * 2008-11-07 2012-02-28 4ЭсЦэ АГ Комбинированная терапия, включающая ингибитор dhodh и метотрексат, для лечения аутоиммунного заболевания
EP2210615A1 (en) * 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
CN103826624A (zh) * 2011-08-30 2014-05-28 富山化学工业株式会社 类风湿性关节炎等自身免疫疾病的处置的改善方法
EP2594271A1 (en) * 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
CN103315985A (zh) * 2013-05-16 2013-09-25 南京市鼓楼医院 Fingolimod在制备抑制肝癌肝内转移药物中的应用
WO2017075559A1 (en) * 2015-10-30 2017-05-04 E. I. Du Pont De Nemours And Company Dihydroorotate dehydrogenase inhibitor compositions effective as herbicides
WO2018157843A1 (zh) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
US20220227720A1 (en) 2019-05-07 2022-07-21 Universitat Hamburg Dhodh inhibitors and their use as antiviral agents
EP4228640A1 (en) * 2020-10-15 2023-08-23 ASLAN Pharmaceuticals Pte Ltd Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
EP4119138A1 (en) 2021-07-12 2023-01-18 Universität Hamburg Dhodh inhibitors and their use as antiviral agents
WO2023204754A1 (en) * 2022-04-21 2023-10-26 Aslan Pharmaceuticals Pte Ltd Treatment of autoimmune skin disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122494A (en) 1995-06-21 2001-08-08 Asta Medica Ag A cartridge for pharmaceutical powder with a measuring device and an integral inhaler for powdered medicines
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
WO2000076489A2 (en) 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
CA2443285C (en) 2001-04-05 2007-08-21 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
PE20030120A1 (es) * 2001-06-19 2003-02-12 Merck & Co Inc Sal amina de un antagonista de receptor de integrin
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
WO2003006424A1 (en) * 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
WO2004056747A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
SE0400234D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
EP1763346A4 (en) 2004-05-21 2009-03-04 Uab Research Foundation COMPOSITION AND METHODS RELATING TO INHIBITORS OF PYRIMIDINE SYNTHESIS
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP2008517059A (ja) 2004-10-19 2008-05-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド 炎症性腸疾患を治療するための（ｚ）−２−シアノ−３−ヒドロキシ−ブタ−２−エン酸−（４’−トリフルオロメチルフェニル）−アミドの使用
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
PE20120395A1 (es) 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
ES2319596B1 (es) * 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2366000T3 (es) * 2007-02-06 2011-10-14 Chelsea Therapeutics, Inc. Nuevos compuestos, métodos para su preparación y uso de los mismos.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2210615A1 (en) * 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2239256A1 (en) * 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2314577A1 (en) * 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

Also Published As

Publication number Publication date
ME02903B (me) 2018-10-20
EP2296663B1 (en) 2017-08-16
DK2296663T3 (en) 2017-10-30
IL209267A0 (en) 2011-01-31
ES2641168T3 (es) 2017-11-08
TW201000103A (en) 2010-01-01
UY31897A1 (es) 2009-08-31
PL2296663T3 (pl) 2018-04-30
TWI440462B (zh) 2014-06-11
EA020193B1 (ru) 2014-09-30
MY155249A (en) 2015-09-30
CN102065866B (zh) 2014-03-26
SG10201609515RA (en) 2017-01-27
CA2728976C (en) 2017-10-17
PT2296663T (pt) 2017-09-11
BRPI0909995A2 (pt) 2015-10-20
CO6321267A2 (es) 2011-09-20
WO2009153043A1 (en) 2009-12-23
AU2009259625B2 (en) 2015-01-15
RS56584B1 (sr) 2018-02-28
AR072174A1 (es) 2010-08-11
EA201100028A1 (ru) 2011-08-30
MX2010013409A (es) 2010-12-22
SG189810A1 (en) 2013-05-31
JP2011524392A (ja) 2011-09-01
JP5507551B2 (ja) 2014-05-28
CY1119643T1 (el) 2018-04-04
CA2728976A1 (en) 2009-12-23
EP2135610A1 (en) 2009-12-23
US8865728B2 (en) 2014-10-21
HUE036639T2 (hu) 2018-07-30
HRP20171667T1 (hr) 2017-12-15
NZ589089A (en) 2012-12-21
CN102065866A (zh) 2011-05-18
AU2009259625A1 (en) 2009-12-23
KR101675601B1 (ko) 2016-11-11
IL209267A (en) 2017-07-31
NO2296663T3 (es) 2018-01-13
SI2296663T1 (sl) 2017-11-30
EP2296663A1 (en) 2011-03-23
PE20110149A1 (es) 2011-03-07
ZA201008041B (en) 2011-06-29
UA114388C2 (uk) 2017-06-12
KR20110036530A (ko) 2011-04-07
LT2296663T (lt) 2017-09-25
US20110129445A1 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
CL2010001359A1 (es) Combinacion farmaceutica que comprende metotrexato y un inhibidor de dihidroorato dehidrogenasa (dhodh) derivado de acido bifenil nicotinico o una sal farmaceuticamente aceptable o n-oxido de los mismos.
DK2074122T3 (da) Pyrido (2, 3-D) pyrimidinon-forbindelser og anvendelse deraf som P13 inhibitorer
WO2013023732A3 (de) Ternesit als anreger für latent-hydraulische und puzzolanische materialien
WO2008124129A3 (en) Treating hiv with a m-csf effector kinase inhibitor like imatinib
CL2007003666A1 (es) Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
UY32062A (es) Inhibidores de beta-secretasa
ATE535526T1 (de) 2-methyl-2-ä4-(3-methyl-2-oxo-8-chinolin-3-yl-2 3-dihydro-imidazo ä4,5-cü chinolinyl)- phenylüpropionitril als lipidkinase-hemmer
BR112014002993A2 (pt) afunilamento de conversão de tipo para conversão de tipo
CR11780A (es) Nuevo proceso para la sintesis de ivabradina y sales de adicion resultantes con un acido farmaceuticamente aceptable (solicitud divisonal)
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
DK2069324T3 (da) Fusioneret aminopyridin som hsp90-inhibitorer
BR112012008317A2 (pt) produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
ECSP099049A (es) Nuevas indicaciones para los inhibidores directos de la trombina en el campo cardiovascular
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
CL2007002330A1 (es) Compuestos derivados de oxo aza antraceno; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el rechazo de trasplante, artritis reumatoide, artritis psoriatica, esclerosis multiple, asma, entre otras.
CL2011002216A1 (es) Sal de adicion de una amina que contiene uno o mas grupos hidroxilo y/o carboxilicos con un derivado de acido aminonicotinico, composicion y combinacion farmaceuticas; y su uso para tratar artritis reumatoide, espondilitis anquilosante, esclerosis multiple, psoriasis, entre otras.
UY30410A1 (es) Aminopirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos
ECSP13013093A (es) Composiciones líquidas de limpieza de sal
WO2008094599A3 (en) Modified rna ligase for efficient 3' modification of rna
UY30409A1 (es) Pirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos.
AR059357A1 (es) Formulaciones farmaceuticas
WO2007090002A3 (en) Alignment correction system and methods of use thereof
GT200900217A (es) Nuevos compuestos triciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
AR059696A1 (es) Medicamentos que contienen fluoroquinolonas